Beta-Glucan Market
The market for Beta-Glucan was estimated at $565 billion in 2025; it is anticipated to increase to $845 billion by 2030, with projections indicating growth to around $1.27 trillion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Beta-Glucan Market Outlook
Revenue, 2025
$565B
Forecast, 2035
$1.27T
CAGR, 2026 - 2035
8.4%
The Beta-Glucan industry revenue is expected to be around $564.8 billion in 2026 and expected to showcase growth with 8.4% CAGR between 2026 and 2035. Building on this outlook, the Beta Glucan market has become a strategically important segment within the global bioactive ingredients landscape, supported by strong clinical validation in cardiovascular support, metabolic balance, and immune health. Demand is increasingly concentrated in Food & Beverage and Dietary Supplement applications, which together account for 73.0% of industry revenue, as manufacturers fortify cereals, bakery products, beverages, and nutraceutical formulations to deliver recognizable health benefits and premium positioning. Soluble Beta Glucan formats, which generated $354.13 billion in sales in 2025, are especially valued for their processability, stability, and high physiological efficacy, enabling brand owners to differentiate through science backed claims related to cholesterol management and digestive wellness.
Beta Glucan is a naturally occurring soluble dietary fiber and biologically active polysaccharide obtained mainly from oats, barley, yeast, and selected mushrooms, characterized by its viscosity, molecular weight profile, and capacity to modulate key elements of the human immune system. Within the Food & Beverage sector it is incorporated into bakery items, snacks, dairy alternatives, and fortified drinks to enhance texture while delivering heart health and blood glucose support, whereas in the Dietary Supplement segment it is formulated into capsules, tablets, and powdered blends that target immune health, metabolic resilience, and overall vitality. Beyond these dominant uses, Beta Glucan is expanding into pharmaceutical and personal care applications, where its bioactive properties are being leveraged in wound care, dermatological, and anti aging formulations. Recent trends driving demand include the move toward plant based and clean label formulations, the rise of personalized nutrition platforms, and progress in extraction and purification technologies that improve the performance of soluble Beta Glucan in complex formulations, while intensifying global interest in gut health and holistic wellness solutions that feature this ingredient as a core functional component.
Market Key Insights
The Beta-glucan market is projected to grow from $564.8 billion in 2025 to $1.27 trillion in 2035. This represents a CAGR of 8.4%, reflecting rising demand across Food & Beverage, Dietary Supplements, and Pharmaceutical.
Tate & Lyle PLC, Kerry Group PLC, and Angel Yeast are among the leading players in this market, shaping its competitive landscape.
U.S. and China are the top markets within the Beta Glucan market and are expected to observe the growth CAGR of 6.1% to 8.8% between 2025 and 2030.
Emerging markets including India, Brazil and South Korea are expected to observe highest growth with CAGR ranging between 8.1% to 10.5%.
Transition like Shift To Evidence-Backed Formulations is expected to add $66 billion to the Beta Glucan market growth by 2030.
The Beta Glucan market is set to add $700 billion between 2025 and 2035, with manufacturer targeting Dietary Supplement & Pharmaceuticals Application projected to gain a larger market share.
With
convergence of gut microbiome research and personalized nutrition elevating beta glucan demand, and
Advances in beta glucan extraction technologies enabling scalable, high-purity functional ingredients, Beta Glucan market to expand 124% between 2025 and 2035.
Opportunities in the Beta-Glucan
North American consumers increasingly prioritize immune support, driving demand for Beta Glucan supplements across pharmacies and e commerce channels. Soluble Beta Glucan dominates, supported by clinical evidence for respiratory health, vaccine response, and gut health modulation. With the soluble segment projected to rise from $354.13 to $522.75 billion by 2030 at 8.1% CAGR, major untapped potential lies in formulations for seniors and immunocompromised adults. Collaborations between ingredient suppliers and sports nutrition brands can also accelerate premium, science backed product launches across North America.
Growth Opportunities in North America and Asia-Pacific
In North America, dietary supplements represent the most relevant application for Beta Glucan, as consumers increasingly seek Beta Glucan supplements for immune health, cholesterol management, and metabolic support, while food and beverage formats play a strong but complementary role through ready to eat cereals, bakery, and functional beverages. Competitive intensity is high, with established nutraceutical brands, major cereal and bakery manufacturers, and specialty ingredient formulators all competing on differentiated oat Beta Glucan, yeast Beta Glucan, and advanced delivery systems that enhance bioavailability and sensory performance. Top opportunities include premium, clinically supported formulations positioned around heart health and gut health, line extensions in plant based functional foods that use cereal Beta Glucan and other soluble fiber for clean label positioning, and private label collaborations with large retail chains to capture value conscious but health aware consumers. Key regional drivers include high awareness of dietary fiber benefits, favorable regulatory frameworks for structure function claims on Beta Glucan for cardiovascular risk reduction, strong penetration of e commerce for nutraceuticals, and an aging population that prioritizes preventive healthcare and evidence based functional ingredients.
In Asia Pacific, food and beverage applications are the primary growth engine for Beta Glucan, with rapid integration into staple foods, instant beverages, and dairy alternatives, while pharmaceuticals and dietary supplements form an expanding secondary layer in markets with strong traditional medicine and wellness cultures. Competition is fragmented, led by large regional food conglomerates, domestic functional beverage brands, and local pharmaceutical and nutraceutical manufacturers that increasingly incorporate oat Beta Glucan and yeast Beta Glucan into differentiated products for immune health and lifestyle disease management. Top opportunities lie in fortifying everyday foods with Beta Glucan to address rising rates of diabetes and cardiovascular conditions, co developing convenient functional foods that combine cereal Beta Glucan with botanicals familiar to local consumers, and expanding sachet based or single serve Beta Glucan supplements tailored to on the go urban lifestyles. Key regional drivers include accelerating urbanization, a growing middle class willing to pay for functional foods with clean label positioning, government emphasis on preventive healthcare and reduction of non communicable diseases, and rising consumer recognition of soluble fiber and dietary fiber as essential components of holistic gut health and long term wellness.
Market Dynamics and Supply Chain
01
Driver: Convergence of gut microbiome research and personalized nutrition elevating Beta Glucan demand
Rapid convergence of gut microbiome science and personalized nutrition is also significantly accelerating global Beta Glucan adoption. On one side, advanced metagenomics, high throughput sequencing, and multi omics platforms are also revealing how Beta Glucan modulates gut health, short chain fatty acid production, and systemic immune health, positioning oat Beta Glucan and yeast Beta Glucan as key prebiotic dietary fiber components in premium functional foods and nutraceuticals. At the same time, data driven personalized nutrition ecosystems, including microbiome testing, digital diet coaching apps, and precision dietary supplements, are also integrating clinically profiled Beta Glucan formats tailored to individual inflammatory, metabolic, and cholesterol reduction risk profiles. These dual trends are also enabling targeted product development around condition specific Beta Glucan blends, age and lifestyle segmented formulations, and subscription based immune support programs, particularly in sports nutrition, healthy aging, and metabolic health platforms, thereby deepening penetration across both developed and fast growing emerging consumer health markets.
Next generation extraction and purification technologies are also transforming Beta Glucan into a more versatile functional ingredient for manufacturers. Enzyme assisted extraction, controlled molecular weight fractionation, and membrane filtration are also delivering highly standardized, water dispersible Beta Glucan concentrates with improved sensory profiles for beverages, dairy alternatives, and ready to drink immune health formulations. Cleaner, solvent free processing and inline quality analytics are also reducing variability in structure and bioactivity, enabling reliable dosing for pharmaceutical applications and high performance cosmeceuticals. These process innovations are also also lowering production costs and supporting large scale, traceable sourcing from cereal and microbial feedstocks, reinforcing Beta Glucan competitiveness against alternative dietary fiber and immune support actives.
02
Restraint: Fragmented global regulatory frameworks and restrictive health claim approvals constrain commercialization of Beta Glucan products
Divergent regional regulations for Beta Glucan in functional foods, nutraceutical formulations, and dietary supplements limit the ability of manufacturers to communicate clear benefits such as cholesterol reduction and immune health, forcing companies to use conservative labelling that weakens consumer perception of value and reduces willingness to pay premium prices; for example, strict health claim approval processes in Europe compared with more flexible regimes in parts of Asia delay cross border product launches, increase compliance costs, and discourage investment in innovative oat Beta Glucan and yeast Beta Glucan applications, collectively dampening revenue growth and slowing category expansion across the global Beta Glucan market
03
Opportunity: High purity Beta Glucan applications in dermatology and cosmeceuticals across Asia Pacific and Functional foods fortified with Beta Glucan for cardiovascular health in Europe
Across Asia Pacific, growth in premium skincare and cosmeceuticals is creating demand for high purity Beta Glucan as a multifunctional active for sensitive and aging skin. Brands in Korea, Japan, and China increasingly use soluble Beta Glucan for hydration, barrier repair, and anti inflammatory benefits, while insoluble formats enable delivery systems and textures. With the global insoluble segment forecast to reach $322.61 billion by 2030 at 8.9% CAGR, the fastest growth is expected in cosmetic grade ingredients targeting post procedure recovery and microbiome friendly formulations.
In Europe, cardiovascular disease prevention and cholesterol management are reshaping functional foods, positioning Beta Glucan as a natural fiber for heart health. Demand is rising for oat and barley based cereals, baked goods, and dairy alternatives with clinically effective soluble Beta Glucan doses. The global soluble categories expansion from $354.13 to $522.75 billion by 2030 underpins growth, yet opportunities remain underdeveloped in private label retail, senior nutrition, and plant based beverages. Strategic partnerships with food manufacturers can scale fortified nutritious staples rapidly.
04
Challenge: Volatile raw material supply and pricing pressures undermine scalable, cost effective production of Beta Glucan
Dependence on agricultural inputs such as oats and barley, combined with energy intensive extraction technologies, exposes Beta Glucan producers to crop failures, climate variability, logistics disruptions, and fluctuating commodity prices, which compress margins and make Beta Glucan less competitive versus alternative dietary fiber and clean label ingredients; for instance, spikes in oat prices and fermentation costs have led food and beverage manufacturers to reformulate away from higher dosage Beta Glucan in some functional food and beverage lines, curbing volume growth, shifting demand toward lower concentration products, and ultimately constraining the overall monetization potential of Beta Glucan across food, beverage, supplement, and cosmetic applications.
Supply Chain Landscape
1
Raw Material Supply
Angel Yeast Co. Ltd.Associated British Foods PLC
2
Beta-Glucan Extraction
DSM-FirmenichAngel Yeast Co. Ltd
3
Beta-Glucan Ingredients
Tate & Lyle PLCKerry Group PLC
4
End-Use
Functional foods & BeveragesDietary fiber supplementsImmune health products
1
Raw Material Supply
Angel Yeast Co. Ltd.Associated British Foods PLC
2
Beta-Glucan Extraction
DSM-FirmenichAngel Yeast Co. Ltd
3
Beta-Glucan Ingredients
Tate & Lyle PLCKerry Group PLC
4
End-Use
Functional foods & BeveragesDietary fiber supplementsImmune health products
Use Cases of Beta-Glucan in Food & Beverage & Dietary Supplements
Food & Beverage : In Food & Beverage, Beta Glucan is increasingly incorporated into beverages, bakery, dairy alternatives, and ready meals, driving an estimated $219.14 billion in 2025 revenue with an expected 8.5% CAGR between 2026 and 2030 as brands expand fiber enriched functional foods positioned for heart health and cholesterol reduction. This application predominantly uses soluble Beta Glucan, particularly oat Beta Glucan and barley derived cereal Beta Glucan, which disperses easily in liquids, improves viscosity and mouthfeel, and enables partial fat and sugar replacement while maintaining a clean label profile. Soluble Beta Glucan leads overall demand with around 62.7% share in 2025, reflecting its strong fit for clear drinks, smoothies, yogurts, and plant based formulations, while insoluble fractions are selectively used in high fiber baked goods for texture and satiety. Tate & Lyle PLC leverages its expertise in soluble dietary fibers, texturants, and sweetener systems to offer Beta Glucan solutions that integrate seamlessly into mainstream and premium formulations, while Kerry Group PLC differentiates with application know how in taste systems and nutrition systems that combine Beta Glucan with proteins, flavorings, and stabilizers. Angel Yeast Co. Ltd., DSM Firmenich, and Associated British Foods PLC strengthen their Food & Beverage positions through cereal and yeast processing capabilities, extensive ingredient portfolios, and global technical support teams that co develop Beta Glucan concepts with multinational food manufacturers.
Dietary Supplements : Beyond mainstream foods, Dietary Supplements represent a fast growing channel for Beta Glucan, formulated into capsules, tablets, gummies, sachets, and powdered drink mixes, with the segment projected to reach around $193.16 billion in 2025 and expand at an expected 9.1% CAGR from 2026 to 2030 as consumers seek immune support, metabolic health, and convenient preventive nutrition. This end use primarily utilizes yeast Beta Glucan, typically an insoluble 1,3/1,6 structure standardized for bioactive content, complemented by highly purified soluble oat Beta Glucan for cardiovascular and glycaemic benefits in advanced Beta Glucan supplements. The combination of insoluble and soluble Beta Glucan allows formulators to position products for immune resilience, gut health, and blood lipid management while keeping dosage forms compact and stable over shelf life. DSM Firmenich is strongly positioned in this arena through its science driven nutraceutical portfolio, clinical substantiation, and regulatory expertise, enabling premium Beta Glucan concepts with differentiated positioning where permitted. Kerry Group PLC integrates Beta Glucan into broader wellness platforms that combine probiotics, postbiotics, and proteins, while Angel Yeast Co. Ltd. capitalizes on deep fermentation know how to supply concentrated yeast Beta Glucan ingredients; Tate & Lyle PLC and Associated British Foods PLC add value via customized premixes, flavours, and sweetener systems that enhance palatability and adherence in daily supplement routines.
Pharmaceutical : At the more regulated end of the Beta Glucan value chain, Pharmaceutical Applications encompass prescription drugs, over the counter products, and clinical nutrition, with the segment expected to generate about $88.67 billion in 2025 and grow at approximately 7.7% CAGR through 2030 as research into immune modulation and supportive care continues. Manufacturers in this space predominantly employ high purity insoluble yeast or fungal Beta Glucan with defined 1,3/1,6 linkages, which is incorporated into oral solids, topical formulations, and parenteral products, while selected soluble Beta Glucan grades are explored for controlled release matrices and bioactive coating systems. The key advantages in pharmaceutical use include the potential to influence host defence mechanisms, support recovery in vulnerable populations, and enhance the performance of certain drug delivery systems, all under stringent quality, traceability, and pharmacopeial compliance. DSM Firmenich maintains a strong position as a provider of pharmaceutical grade ingredients, leveraging robust quality systems, technical documentation, and collaborative development with drug manufacturers around Beta Glucan and complementary actives. Angel Yeast Co. Ltd. extends its fermentation and purification capabilities to pharma oriented yeast Beta Glucan solutions, while Kerry Group PLC, Tate & Lyle PLC, and Associated British Foods PLC participate through medical nutrition, oral solid dose excipients, and specialized formulations that integrate Beta Glucan into evidence based therapeutic and peri hospital nutrition products.
Recent Developments
Recent developments in the Beta Glucan market highlight accelerating demand for immune health supplements, functional foods, and cosmeceuticals, driven by rising consumer focus on natural immunity support and gut health. Advanced extraction technologies for oat Beta Glucan and yeast Beta Glucan are improving purity, solubility, and formulation flexibility, supporting clean label nutraceuticals. A key trend is the integration of Beta Glucan into personalized nutrition and sports nutrition products, aligning with clinical research on cholesterol reduction and metabolic health.
May 2023 : DSM and Firmenich complete their merger, forming DSM Firmenich and significantly expanding its capabilities in human nutrition and health ingredients; this is expected to accelerate innovation and commercialization of Beta Glucan solutions for immune health, functional foods, and dietary supplements, thereby supporting deeper penetration of Beta Glucan into mainstream consumer products worldwide
May 2022 : DSM and Firmenich announce their intention to merge, signaling a strategic pivot toward higher value nutrition and wellness platforms that include specialty fibers and polysaccharides such as Beta Glucan, oat Beta Glucan, and yeast Beta Glucan, which raised expectations of intensified competition, new partnerships, and capacity investments across the global Beta Glucan market.
Impact of Industry Transitions on the Beta-Glucan Market
As a core segment of the F&B industry,
the Beta-Glucan market develops in line with broader industry shifts.
Over recent years, transitions such as Shift To Evidence Backed Formulations and Expansion Into Advanced Skincare have redefined priorities
across the F&B sector,
influencing how the Beta-Glucan market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Shift To Evidence Backed Formulations
The Beta Glucan market is undergoing a significant transformation, evolving from a generic immune health additive to a clinically validated active ingredient, bolstered by standardized dosing and robust human trial data. This strategic shift is prompting leading dietary supplement brands to reformulate their products with high purity oat and yeast Beta Glucan, targeting key health areas such as cholesterol management, gut health, and metabolic support. As a result, R&D pipelines are being reshaped to prioritize validated soluble fiber ingredients, aligning with heightened regulatory expectations across cardiovascular health, sports nutrition, and healthy aging sectors. This transition is projected to drive an impressive $66 billion in market growth by 2030, underscoring the critical importance of evidence backed formulations in capturing consumer demand and enhancing market competitiveness.
02
Expansion Into Advanced Skincare
In personal care, Beta Glucan is evolving from a niche moisturizing agent to a hero ingredient in advanced skincare, cosmeceuticals, and dermatology linked products. Brands are leveraging yeast Beta Glucan and mushroom extracts for barrier repair, redness reduction, and post procedure recovery, integrating them with probiotics and ceramides. This transition is influencing formulation strategies for sensitive skin, scalp care, and medical grade aesthetics, creating new premium segments and licensing models, while encouraging closer collaboration between cosmetic chemists, dermatologists, and pharmaceutical manufacturers on clinically substantiated topical claims.